The present study examined the effects of N-desmethylclozapine (NDMC), a biologically active metabolite of the atypical antipsychotic clozapine, at cloned human opioid receptors stably expressed in Chinese hamster ovary (CHO) cells and at native opioid receptors present in NG108-15 cells and rat brain. In CHO cells expressing the d-opioid receptor (CHO/DOR), NDMC behaved as a full agonist both in stimulating [ 
INTRODUCTION
N-desmethylclozapine (NDMC) and clozapine N-oxide (CNOX) are two major metabolites of the atypical antipsychotic clozapine, which lacks extrapyramidal side effects, displays high efficacy in refractory schizophrenia, improves negative symptoms, and reduces the risk of suicide in schizophrenia (Meltzer, 2002; Meltzer et al, 2003) . Whereas CNOX can be rapidly re-converted to clozapine, NDMC reaches considerable plasma concentrations ranging from 49 to 140% of those of the parent compound in schizophrenic patients (Centorrino et al, 1994; Olesen et al, 1995; Aravagiri and Marder, 2001; Frazier et al, 2003) and from 50 to 220% in the rat (Baldessarini et al, 1993; Weigmann et al, 1999) . In the rat brain, concentrations of NDMC higher than those in serum have been detected following clozapine administration, indicating that the metabolite can cross the blood-brain barrier (Weigmann et al, 1999) . Moreover, a higher ratio of NDMC to clozapine in plasma was found to correlate positively with clinical improvements, indicating that NDMC may contribute to the clinical efficacy of clozapine (Weiner et al, 2004) .
Pharmacological studies have shown that NDMC shares the clozapine ability to bind to a large array of neurotransmitter receptor systems. Thus, NDMC was found to display high affinity for serotonin 5HT 2C and 5HT 2A receptors, to potently block 5-HT 2C receptor-stimulated phosphoinositide hydrolysis in rat choroid plexus, and to bind to striatal dopamine (DA) D 1 and D 2 receptors (Kuoppamaki et al, 1993) . Following in vivo administration, NDMC increased the expression of the immediate-early gene c-fos in rat brain with a regional specificity similar to that displayed by clozapine (Young et al, 1998) .
An important feature of clozapine is its ability to bind with high affinity to acetylcholine (ACh) muscarinic receptors and to act as a mixed agonist/antagonist (Zorn et al, 1994; Zeng et al, 1997; Olianas et al, 1997 Olianas et al, , 1999 Michal et al, 1999) . A similar property has recently been demonstrated for NDMC. Thus, in cell lines expressing the cloned human muscarinic receptor subtypes NDMC has been found to act as a partial agonist with potencies and efficacies higher than those of the parent drug (Sur et al, 2003; Weiner et al, 2004; Davies et al, 2005) . In CA1 hippocampal neurons, NDMC was found to potentiate NMDA-mediated currents (Sur et al, 2003) and to induce phosphorylation of extracellular signal-regulated kinases (ERK) by activating muscarinic M 1 receptors (Weiner et al, 2004) . This receptor has also been shown to mediate the increases in cortical ACh and DA release observed following systemic administration of NDMC in freely moving rats (Li et al, 2005) . Besides stimulating muscarinic receptors, NDMC has been recently shown to act as a partial agonist in transfected cell lines overexpressing the human DA D 2 or D 3 receptor and the G protein Go, whereas clozapine behaved as an inverse agonist (Burstein et al, 2005) .
Although the precise molecular mechanisms mediating the atypical antipsychotic profile of clozapine are still unknown, it is likely that both antagonist and agonist actions of the drug and its metabolite(s) at multiple neurotransmitter receptor systems may be involved (Roth et al, 2004) . As NDMC is less characterized than its parent compound, the understanding of the role of NDMC in the therapeutic activity of clozapine requires the definition of its whole spectrum of pharmacological activities and molecular targets.
Previous studies have investigated the opioid system as one of the sites of action of clozapine in the brain. Chronic administration of clozapine to rats and mice increased proenkephalin mRNA expression in striatum and nucleus accumbens, dynorphin levels in substantia nigra (Angulo et al, 1990) , and the density of brain m-and d-opioid receptors (Zang et al, 1995) . In mice, the acute injection of clozapine was found to produce analgesia using the tail-flick test and this effect was antagonized by naloxone and selective m-and k-opioid receptor antagonists (Schreiber et al, 1999) . Studies in vitro have shown that clozapine inhibited [ 3 H]Met-enkephalin binding to synaptosomeenriched fractions of rat whole brain and hippocampus with a micromolar potency (Somoza et al, 1981) . In Xenopus oocytes co-injected with either the d-or k-opioid receptor mRNA and the G protein-activated inwardly rectifying potassium channel, Kobayashi et al (1998) reported that clozapine displayed both d-and k-receptor agonist activity and suggested that this effect may contribute to the antinociceptive and proconvulsant effect of the drug. Although early studies suggested possible links between opioids and schizophrenia (Pickar et al, 1982; Schmauss and Emrich, 1985; Brizer et al, 1985; Schmauss et al, 1987; Gulya, 1990) , the involvement of the opioid system in the therapeutic actions of clozapine has been generally overlooked, mostly because of the low affinity of clozapine for the opioid receptors.
In the present study we have examined the interaction of NDMC with each of the cloned human opioid receptors individually expressed in Chinese hamster ovary (CHO) cells and evaluated its receptor activity by using different functional assays. Moreover, we investigated the actions of NDMC at opioid receptors naturally expressed in NG 108-15 cells and rat brain. In each receptor system, the effects of clozapine and CNOX were also analyzed.
Part of this study has previously been presented in an abstract form (Onali and Olianas, 2004a) . 
MATERIALS AND METHODS

Materials
Cell Culture
CHO-K1 cells (American Type Culture Collection) stably expressing the human d-opioid receptor (CHO/DOR) (2250 fmol/mg protein), m-opioid receptor-1 (CHO/MOR-1) (350 fmol/mg protein), k-opioid receptor (CHO/KOR) (2800 fmol/mg protein), and nociceptin/orphanin FQ receptor (CHO/NOP) (400 fmol/mg protein) were generated by PolyFect (Qiagen) transfection with cDNAs cloned into pcDNA3.1 + vector (Invitrogen). The cDNAs were obtained from either UMR cDNA Resource Center (Rolla, MO, USA) or Top Gene Tec. (Montreal, Canada). Cells were grown as a monolayer culture in tissue culture flasks (Falcon) that were incubated at 371C in a humidified atmosphere (5% CO 2 ) in Ham's F12 medium (GIBCO BRL) containing L-glutamine and sodium bicarbonate and supplemented with 10% heat inactivated foetal calf serum (GIBCO BRL), 0.5% penicillin/ streptomycin (GIBCO BRL) and either 350 mg/ml hygromycin (GIBCO BRL) for CHO/DOR or 400 mg/ml geneticin (GIBCO BRL) for the other recombinant cell lines.
NG108-15 neuroblastoma Â glioma hybrid cells (European Collection of Cell Cultures) were grown in DMEM supplemented with 2 mM L-glutamine, 0.1 mM hypoxanthine, 16 mM thymidine, 0.4 mM aminopterin, 0.5% penicillin/ streptomycin, and 10% heat-inactivated foetal calf serum in a humidified 95% air and 5% CO 2 at 371C.
with ice-cold phosphate-buffered saline (PBS) (pH 7.4). Thereafter, the cells were scraped into an ice-cold buffer containing 10 mM HEPES/NaOH (pH 7.4) and 1 mM EDTA, and lysed with a Dounce tissue grinder. The cell lysate was centrifuged at 1000g for 2 min at 41C. The supernatant was collected and centrifuged at 32 000g for 20 min at 41C. The pellet was resuspended in the homogenization buffer at a protein concentration of 1.0-1.5 mg/ml and stored in aliquots at À801C.
Dissection of Rat Brain Regions and Membrane Preparation
Male Sprague-Dawley rats (200-300 g) were used. Animals were maintained in a 12 h light/dark cycle with food and water ad libitum. Experiments were performed according to the principles of laboratory animal care (Law on animal experiments in Italy, DL 116/92). Rats were killed by decapitation and the brain areas of interest were rapidly dissected as previously described Olianas, 2002, 2004b) . The frontal lobes and the tissue samples from individual slices were homogenized in an ice-cold buffer containing 10 mM HEPES-NaOH, 1 mM EGTA, 1 mM MgCl 2 (pH 7.40) using a Teflon-glass tissue grinder. The homogenate was centrifuged at 27 000g for 20 min at 41C. The pellet was resuspended in the same buffer at a protein concentration of 0.8-1.0 mg/ml and used immediately for adenylyl cyclase assays or stored at À801C for binding assays. For each experiment, a fresh tissue preparation was used.
Assay of [
S]GTPcS Binding
Cell and tissue membranes were diluted 10-fold in an ice-cold buffer containing 10 mM HEPES/NaOH and 1 mM EDTA (pH 7.4), centrifuged at 32 500g for 30 min at 41C and resuspended in the same buffer containing 0.1% bovine serum albumin (BSA). The binding of [ 35 S]GTPgS was assayed in a reaction mixture (final volume 100 ml) containing 25 mM HEPES/NaOH (pH 7.4), 10 mM MgCl 2 , 1 mM EDTA, 150 mM KCl, 10 kallikrein inhibitor units (KIU) of aprotinin, 10 mM leupeptin, 10 mM bestatin, 1.0 nM [ 35 S]GTPgS. GDP was added at the concentration of 5 mM for CHO/NOP, 10 mM for CHO/ MOR-1, 30 mM for CHO/KOR and CHO/DOR, and 50 mM for rat brain membranes. Membranes (2-4 mg of protein) were preincubated for 20 min at 301C with the test compounds. For each compound, control samples received an equal volume (10 ml) of vehicle to determine the basal values. The reaction was started by the addition of [
35 S]GTPgS and continued for 40 min at 301C. The incubation was terminated by the addition of 5 ml of icecold buffer containing 10 mM HEPES/NaOH (pH 7.4) and 1.0 mM MgCl 2 , immediately followed by rapid filtration on glass fiber filters (Whatman GF/C) presoaked in the same buffer. The filters were washed twice with 5 ml of buffer and the radioactivity trapped was determined by liquid scintillation spectrometry. Nonspecific binding was determined in the presence of 50 mM GTPgS. Assays were performed in duplicate. 
Assay of Adenylyl Cyclase
The adenylyl cyclase activities of dorsal striatum, nucleus accumbens, and frontal cortex were assayed in a reaction mixture (final volume 100 ml) containing 50 mM HEPES/ NaOH (pH 7.4), 2.3 mM MgCl 2 , 0.3 mM EGTA, 0.05 mM [a- 
Receptor Binding Assays
Radioligands used for receptor binding assays were [ For each compound, control samples received an equal volume of vehicle. Reactions were terminated by the addition of 5 ml of ice-cold buffer containing 10 mM HEPES/NaOH (pH 7.4) and 1 mM MgCl 2 immediately followed by rapid filtration through glass fiber filters (Whatman GF/C) presoaked with 0.1% polyethylenimine. The filters were washed twice with 5 ml of buffer and the radioactivity trapped was determined by liquid scintillation spectrometry. Assays were performed in triplicate.
Indirect Immunofluorescence Analysis
Cells were grown in tissue culture chamber slides (Nunc Lab-Tek II treated with CC2) and serum starved for 12 h. Following the addition of fresh serum-free medium, the cells were treated with the test compounds and placed in the incubator for 20 min at 371C. Thereafter, the medium was removed and the cells were rapidly washed with PBS. Following fixation with 4% paraformaldehyde in PBS for 10 min, the cells were treated with 0.5% Triton X-100 in PBS for 7 min, and blocked with 10% normal goat serum (NGS) in PBS for 20 min. The cells were then washed and incubated with a rabbit anti phospho-ERK1/2 affinity purified antibody (1 : 1000 dilution in PBS containing 0.25% Triton X-100 and 1.5% NGS; Neuromics, Northfield, MN) overnight at 41C. After washing with PBS, the cells were incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (1 mg/ml in PBS containing 1.5% NGS; Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 45 min at room temperature. After a final washing step, the glass slides were covered with coverslips in Gel Mount aqueous mounting medium (Sigma). The cells were analyzed with a Olympus IX51 microscope and images were captured with a Olympus digital camera. Negative controls were incubated with FITC-conjugated secondary antibody only. The percent of immunolabeled cells was determined by examining at least four fields in each sample and calculated by counting the total number of cells present in each optic field, which ranged from 80 to 100. Cell counting was performed by an investigator unaware of the drug treatment protocol.
Western Blot Analysis
For the assay of ERK1/2 phosphorylation in cell extracts, serum-starved NG-108-15 cells grown in 36 mm Petri dishes were treated with the test compounds as indicated above and cell extracts were prepared by scraping the cells in icecold PBS containing 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 2 mM EDTA, 2 mM EGTA, 4 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 0.1% phosphatase inhibitor cocktail 1 (Sigma), and a protease inhibitor cocktail (100 KIU/ml of aprotinin, 10 mg/ml of leupeptin, 10 mg/ml of soybean trypsin inhibitor, 3 mM pepstatin, and 1 mM phenylmethylsulfonyl fluoride). The samples were sonicated for 5 s in ice-bath and aliquots of the cell extracts containing equal amount of cell proteins were mixed with a 5 Â solution of sample buffer (300 mM Tris-HCl, 10% SDS, 40% glycerol, 10% b-mercaptoethanol, and 0.008% bromophenol blue, pH 6.8), heated at 1001C for 5 min, and subjected to SDSpolyacrilamide gel electrophoresis. The proteins were electrophoretically transferred onto polyvinylidene difluoride membranes (Immobilon-P, Millipore Corp.), according to the method of Towbin et al (1979) . The efficiency of the transfer was controlled by staining the gel with Coomassie Brilliant Blue and by following the transfer of prestained protein standards (Santa Cruz Biotechnology Inc.). Nonspecific binding sites were blocked by incubation in 20 mM Tris-HCl, 137 mM NaCl, and 0.05% Tween-20 (pH 7.6) (TBS-T buffer) containing 5% BSA for 1 h at room temperature. After washing with TBS-T buffer, the membranes were incubated overnight at 41C with the antiphospho-ERK1/2 antibody (1 : 1000 in TBS-T containing 0.1% BSA). For assurance that equivalent amount of total ERK was loaded in each lane, the blots were incubated with an anti-ERK1 affinity purified antibody (1 : 1000) (Neuromics). The membranes were then washed with TBS-T and incubated with a horseradish peroxidase-conjugated second antibody (1 : 10 000 Santa Cruz Biotechnology Inc.) for 45 min at room temperature. Immunoreactive bands were detected by using an enhanced chemiluminescence system (ECL Plus) and ECL Hyperfilm (Amersham). In each experiment, the size of the immunoreactive bands was determined by using molecular weight standards detected with a specific antibody suitable for the ECL system (Santa Cruz Biotechnology Inc.). Band densities were determined by densitometric analysis using the NIH ImageJ software. In each experiment, the optical density of the phospho-ERK1/2 bands was normalized to the density of the corresponding ERK1 internal control.
Protein content was determined by the method of Bradford (1976) using BSA as a standard.
Statistical Analysis
Results are reported as mean7standard error of the mean (SEM). Data from concentration-response curves were analyzed by the program Graph Pad Prism (San Diego, CA, USA.), which yielded agonist concentration producing half-maximal effect (EC 50 values) and maximal effects (E max ). For statistical analysis, the EC 50 values were converted to the logarithmic form (pEC 50 ¼ negative logarithm of EC 50 ) as they are log-normally distributed (Fleming et al, 1972) . The percent of maximal effect (% E max ) by the drugs at the d-opiod receptor was calculated as net maximal effect of the agonist/net maximal effect elicited by DPDPE Â 100. Saturation binding data were analyzed by the LIGAND program (Munson and Rodbard, 1980) . Antagonist potencies in functional assays and radioligand competition curves were analyzed by nonlinear regression analysis and the antagonist inhibitory constant (K i ) was calculated according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . K i values were converted to the logarithmic form (pK i ). The K i /EC 50 ratio was determined to be significantly different from one when the corresponding pK i and pEC 50 values were significantly different. When the difference was not significant, the ratio was considered equal to 1. The efficacy of the opioid receptor ligands in stimulating [ 35 S]GTPgS binding was calculated according to the method described by Ehlert (1985) and Quock et al (1999) , in which efficacy ¼ (E max-A /E max-B ) Â (K i /EC 50 + 1) Â 0.5, where E max-A is the maximal effect elicited by the test compound, E max-B is the maximal effect elicited by DPDPE, respectively, K i is the inhibition constant of the compound obtained from competition binding experiments in the presence of guanine nucleotides, and EC 50 is the concentration of the compound producing half-maximal effect. Statistical analysis was performed by either Student's t-test when comparing two groups and one-way ANOVA followed by Dunnett post hoc test when comparing more than one group.
RESULTS
Effects in CHO Cells Expressing the Cloned Human Opioid Receptors
As shown in Figure 1a , in CHO/DOR cell membranes NDMC elicited a concentration-dependent stimulation of 
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In intact CHO/DOR cells, NDMC inhibited FSK-stimulated cyclic AMP accumulation with a pEC 50 value of 6.4070.04 and a maximal effect corresponding to 7875% decrease of control activity (n ¼ 3) (results not shown). This effect was equal to 9675% of the maximal inhibitory response elicited by DPDPE. Clozapine was significantly less potent (pEC 50 ¼ 5.0570.06, po0.01) and less efficacious (6773% inhibition), whereas CNOX showed little agonist activity, maximally inhibiting cyclic AMP accumulation by 1674% with a pEC 50 of 5.5070.10 (n ¼ 3) (results not shown). In CHO/MOR-1 and CHO/KOR cells, NDMC, clozapine, and CNOX failed to significantly affect FSKstimulated cyclic AMP accumulation at concentrations up to 30 mM (n ¼ 3) (results not shown).
Determination of Ligand-Binding Affinities
Increasing concentrations of NDMC inhibited [ 3 H]NTI binding to CHO/DOR membranes with a competition curve that was best fit by a two-site model, indicating the occurrence of a high-(52.874%, pK i ¼ 7.4270.03) and a low-affinity component (pK i ¼ 5.4770.05) (Figure 3a) . In the presence of guanine nucleotides (30 mM GDP and 1 nM GTPgS), the NDMC competition curve was monophasic and shifted to the right, with a pK i of 5.5770.02. Clozapine inhibited [
3 H]NTI binding with a pattern similar to that of NDMC (Figure 3b ), but with lower pK i values both in the absence (high-affinity component 5073%, pK i ¼ 5.847 0.03; low-affinity component pK i ¼ 4.4670.05) and in the presence of guanine nucleotides (single component with pK i ¼ 4.5570.04). Conversely, CNOX generated monophasic inhibition curves with similar pK i values in the absence (5.5970.05) and in the presence of guanine nucleotides (5.5170.03) (Figure 3c ).
In competition binding experiments performed using CHO/KOR cell membranes and in the absence of added guanine nucleotides, NDMC inhibited the binding of [ 
Determination of d-Opioid Receptor Agonist Efficacy
The efficacies of NDMC and the other two related compounds in stimulating [
35 S]GTPgS binding to CHO/ DOR membranes were determined according to the method of Ehlert (1985) , which takes into consideration both the magnitude of the agonist effect and the extent of receptor occupancy at which half-maximal effect occurred (K i /EC 50 ratio). As shown in Table 1 , NDMC exhibited a high K i /EC 50 ratio and an efficacy value equal to 82% of that displayed by DPDPE, whereas clozapine and CNOX had lower receptor reserve and efficacy values corresponding to 33 and 0.8% of that of the full agonist, respectively.
Effects in NG 108-15 Cells
In NG108-15 cells naturally expressing the d-opioid receptors, NDMC inhibited FSK-stimulated cyclic AMP accumulation almost as effectively as DPDPE (6575% reduction of control activity) and with a pEC 50 value of 5.8070.05 (Figure 4a ). Clozapine was less potent (pEC 50 ¼ 5.0170.06) and less efficacious (4374% inhibition of control activity) than the N-demethylated metabolite, whereas CNOX was inactive. NTI antagonized the 
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NDMC inhibitory effect with a pK i value of 10.1470.01, which was consistent with its d-opioid receptor affinity (Figure 4b ). Immunocytochemical analysis showed that exposure of NG108-15 cells to NDMC (10 mM) for 20 min caused a marked stimulation of ERK1/2 phosphorylation, and this effect was antagonized by the concomitant addition of 1 mM NTI (Figure 5a ). The percent values of immunolabeled cells were: control 2473, NDMC 6075 (po0.05 vs control), NTI 2875 (p40.05 vs control), and NTI + NDMC 3277 (p40.05 vs control) (one-way ANOVA, n ¼ 3). In Western blot analysis using the same primary antibody, NDMC significantly stimulated the labeling of phosho-ERK1/2 immunoreactive bands by 55% and this effect was completely blocked by NTI, which per se caused no change (Figure 5b and c) . (Figure 6a-c) . In the same brain regions, NDMC inhibited FSK-stimulated adenylyl cyclase activity by 3174, 2474, and 2173% (po0.01) with pEC 50 values of 5.8570.06, 5.7370.03, and 5.7670.02, respectively. Conversely, in membranes of rat thalamus, which expresses a low level of d-opioid receptors and a high density of mopioid receptors (Mansour et al, 1995) , [
Effects in Rat Brain Membranes
35 S]GTPgS binding was weakly affected by NDMC (o1073% increase at 10 mM, n ¼ 3), but it was markedly stimulated by DAMGO (16078% increase at 1 mM, n ¼ 3) (results not shown). In membranes of the granule cell layer of the main olfactory 
DISCUSSION
In the present study, we show that the clozapine major metabolite NDMC behaves as selective and efficacious agonist at the d-opioid receptor. In CHO/DOR cells, the drug exhibited full agonist activity in both [
35 S]GTPgS binding and cyclic AMP accumulation assays, and the activity was blocked by TIPP with a potency similar to that displayed in antagonizing DPDPE, demonstrating the mediation by a common recognition site. The functional selectivity for the d-opioid receptor is indicated by the lack of agonist effects in both CHO/MOR-1 and CHO/NOP cells, and by the about 300-to 1000-fold higher threshold concentration for the activation of the k-opioid receptor in CHO/KOR cells. Moreover, in radioligand binding assays, NDMC showed an affinity for the d-opioid receptor, which was about 60-fold higher than that for the k-opioid receptor and a very low affinity for the m-opioid receptor. These results are in agreement with the K i Database of the NIMH psychoactive drug screening program (http://pdsp.cwru. edu/pdsp.php), which reports an NDMC K i value of 127.9 nM for the d-opioid receptors and K i values higher than 10 mM for both m-and k-opioid receptors. As expected for an agonist acting at a G protein-coupled receptor, in CHO/DOR cell membranes NDMC inhibited [ 3 H]NTI binding with shallow competition curves, indicating the presence of a high-and a low-affinity binding site. The addition of guanine nucleotides markedly reduced the fraction of the high-affinity component and shifted the competition curve to describe a single low-affinity binding site. This allosteric regulation by guanine nucleotides has been documented for agonists, but not for antagonists, at the d-opioid receptor (Werling et al, 1988) . When the efficacy was determined, we found that NDMC exhibited a relatively high K i /EC 50 ratio and an efficacy value slightly lower than that of the full agonist DPDPE, indicating that the drug activates d-opioid receptor-mediated G protein signalling with high efficiency.
Previous studies have described partial agonist effects of NDMC at the cloned M 1 -M 5 muscarinic receptors (Sur et al, 2003; Weiner et al, 2004; Davies et al, 2005) and D 2 and D 3 DA receptors (Burstein et al, 2005) with potencies generally comparable to those observed in CHO/DOR cells (pEC 50 (Davies et al, 2005) and of 6.94 (Sur et al, 2003) and phosphoinositide hydrolysis with a pEC 50 of 6.7 (Weiner et al, 2004) . At D 2 and D 3 DA receptors, NDMC displayed agonist activity equal to 35 and 50% of that of pergolide at the concentration of 20 and 30 nM, respectively (Burstein et al, 2005) . NDMC displayed higher potency (K i ¼ 2.9 nM) in antagonizing 5-HT 2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus and [ 3 H]ketanserin binding to 5-HT 2A in rat frontal cortex (K i ¼ 7.4 nM) (Kuoppamaki et al, 1993) .
Clozapine displayed an agonist activity similar to that of its demethylated metabolite, being active in CHO/DOR cells but having little effects in CHO/KOR, MOR-1, and NOP cells. However, as d-opioid receptor agonist, clozapine was much weaker than NDMC. N-desmethylclozapine activates d-opioid receptors P Onali and MC Olianas that displayed by DPDPE, suggesting that the drug activates the d-opioid receptor with a relatively low efficiency. The finding that clozapine possesses agonist activity at the dopioid receptor is in agreement with a previous study by Kobayashi et al (1998) , who reported that in Xenopus oocytes co-injected with the G-protein-activated inwardly rectifying potassium channel and either the d-or k-opioid receptor mRNA, clozapine stimulated the d-opioid receptor more potently and efficaciously (EC 50 ¼ 4.56 mM; 60% of the DPDPE response) than the k-opioid receptor (EC 50 ¼ 30.2 mM; 20% of the U-50,488H response).
Differently from NDMC and clozapine, CNOX was a poor agonist at the d-opioid receptor and failed to affect the other opioid receptor subtypes. Moreover, in competition binding assays, the compound inhibited the [ 3 H]NTI binding to CHO/DOR cell membranes with low affinity and in a guanine nucleotide-insensitive manner, a property typical of receptor antagonist. Indeed, CNOX showed a K i /EC 50 ratio close to unity and an estimated efficacy value less than 1% of that shown by DPDPE, indicating that the compound possesses a very low intrinsic activity.
As heterologous cell lines overexpressing the cloned receptors provide a system with a high stimulus-response efficiency that may greatly affect agonist intrinsic activity, it was important to investigate whether NDMC was able to activate the d-opioid receptor in cell systems expressing receptors, G proteins, and effectors under native conditions. We found that in NG108-15 cells, which endogenously express d-opioid receptors (Evans et al, 1992) , NDMC inhibited FSK-stimulated cyclic AMP accumulation as effectively as DPDPE, clozapine was 25-fold less potent and significantly less efficacious, and CNOX was completely inactive. The involvement of the d-opioid receptor in the NDMC response was demonstrated by the complete and potent blockade by NTI. Moreover, in the same cell system, NDMC induced ERK1/2 phosphorylation by acting at the dopioid receptor, as previously observed for other opioid agonists (Zhang et al, 1999) . In neuronal cells, ERK1/2 is known to participate in molecular pathways regulating learning, memory, and synaptic plasticity (Thomas and Hunganir, 2004) . Previously, it has been reported that in mice the systemic administration of NDMC increased phospho-ERK1/2 immunoreactivity in the hippocampus and this response was blocked by pretreatment with scopolamine, indicating the participation of muscarinic receptors (Weiner et al, 2004) . Studies in rats have shown that clozapine induced ERK1/2 phosphorylation in prefrontal cortex by blocking serotonin 5HT 2A receptors and that ERK1/2 inhibitors prevented clozapine suppression of the conditioned avoidance response, a behavioral index of antipsychotic activity (Browning et al, 2005) . It will be of interest to investigate whether in the brain NDMC can regulate ERK1/2 activity via d-opioid receptors as found in NG108-15 cells.
The ability of NDMC to activate native d-opioid receptor was also examined in distinct rat brain areas, such as dorsal striatum, nucleus accumbens, frontal cortex, and the granule cell layer of main olfactory bulb, which express high to intermediate concentrations of d receptors together with other opioid receptors (Mansour et al, 1995 (Mansour et al, 1995) . These data indicate that NDMC retains the ability to activate d-opioid receptors endogenously expressed in brain. It is noteworthy that in the brain membrane preparations clozapine displayed negligible agonist activity, in agreement with the low efficacy value showed in CHO/DOR cells.
While in CHO/DOR cells NDMC stimulated [ 35 S]GTPgS binding with a nanomolar potency, the compound was significantly less potent in activating the native d-opioid receptor with pEC 50 values ranging from 5.73 to 6.18. Nonetheless, these values are within the range of NDMC plasma concentrations (175-435 ng/ml; 0.6-1.4 mM) measured in schizophrenics following chronic treatment with clozapine (Centorrino et al, 1994; Olesen et al, 1995; Aravagiri and Marder, 2001; Frazier et al, 2003) . The concentrations reached by NDMC in the human brain under these conditions are unknown. Studies in rats have reported that brain levels of NDMC were relatively low as compared to those of clozapine (Baldessarini et al, 1993) . However, in the study of Weigmann et al (1999) , who analyzed the blood/brain distribution of clozapine and NDMC under steady-state conditions, the brain levels of NDMC reached a value of 2000 ng/g and were about threefold lower that those of clozapine. Although these values do not allow the determination of the drug concentrations in the biophase, they are comparable with the potencies of NDMC in activating the d-opioid receptor in rat brain membranes. Moreover, whereas clozapine has higher affinity than NDMC at muscarinic M 1 and DA D 2 /D 3 receptors and potently antagonizes NDMC agonist activity at these receptors (Sur et al, 2003; Weiner et al, 2004; Burstein et al, 2005; Li et al, 2005) , the affinity of clozapine for the d-opioid receptor is more than 10-fold lower than that of NDMC, suggesting that in the brain the demethylated metabolite could activate the receptors even in the presence of higher concentrations of the parent drug.
Clinical studies on the role of opioids in schizophrenia have yielded conflicting results, as some investigations reported beneficial effects with either opioid agonists (Brizer et al, 1985; Schmauss et al, 1987) or antagonists (Berger et al, 1981; Marchesi et al, 1995) , whereas others observed either impairment of schizophrenic symptoms (Gerner et al, 1980; Judd and Janowsky, 1981) or no effects (Naber, 1988; Wonodi et al, 2004) with similar treatments. Moreover, most of the studies employed nonselective agents, making the understanding of the role of each opioid receptor difficult. Thus, at present the relevance of the selective d-opioid agonist activity of NDMC for the antipsychotic action of clozapine remains uncertain. Nonetheless, it is possible that this property may have implications for clozapine activity in mood disorders. A number of evidence from animal studies indicate that d-opioid receptors are highly expressed in cortical and limbic regions and are involved not only in analgesia, but also in the control of cognitive and emotional functions and motivation-related behaviors. Mice deficient in pre-proen-kephalin, which generates the d-preferring agonists enkephalins, showed increased levels of anxiety and males displayed offensive aggressiveness (Konig et al, 1996) . Moreover, mice, in which the d-opioid receptor gene has been disrupted by targeted deletion of exon 1, exhibited anxiogenic effects in the elevated-plus-maze and the lightdark box behavioral tests, whereas m-opioid receptor deficient mice showed anxiolytic effects (Filliol et al, 2000) . Importantly, mice lacking the d-opioid receptors exhibited a depressive-like behavior in tests that reliably predict antidepressant effects in humans (Filliol et al, 2000) . Thus, it can be proposed that an increased d-opioid receptor activity by NDMC may contribute, at least in part, to the reported clinical efficacy of clozapine in ameliorating psychotic mood disorders (McElroy et al, 1991) , in reducing the risk of suicide in schizophrenia and schizoaffective disorder (Meltzer et al, 2003; Kerwin and Bolonna, 2004) and in suppressing aggressive behaviors in psychotic patients (Kraus and Sheitman, 2005) . A relevant role of dopioid receptors in depression is further supported by pharmacological data showing that the nonpeptidic dopioid receptor agonists ( + )BW373U86 and SNC80 exerted antidepressive effects in animal models (Broom et al, 2002) and potentiated D 1 and D 2 DA receptor stimulation (Spina et al, 1998) , which may improve cognition and depression, and that, conversely, d-opioid receptor antagonists caused anxiety-related behaviors (Saito et al, 2005) . Like antidepressant drugs (Nibuya et al, 1995) , d-opioid receptor agonists have been found to increase the hippocampal and cortical synthesis of brain-derived neurotrophic factor (BDNF) (Torregrossa et al, 2004) , which is known to regulate neuronal development and plasticity and has been shown to possess antidepressant activity (Shirayama et al, 2002) . Finally, selective activation of d-opioid receptor has been shown to reverse the catalepsy induced by DA receptor antagonists and the parkinsonian symptoms in the MPTPtreated marmoset (Hille et al, 2001) and to cause convulsions (Comer et al, 1993) , a relatively frequent side effect of clozapine therapy.
In conclusion, the present study demonstrates that NDMC behaves as a selective and efficacious d-opioid agonist in recombinant and native receptor systems. This unique property provides the compound with the ability to affect those molecular pathways and neuronal circuits of the central opioid system specifically involved in the control of emotion and motivation and therefore may contribute to important features of the clozapine therapeutic action, particularly in improving mood disorders.
